509 related articles for article (PubMed ID: 30744691)
1. Cancer-cell-secreted CXCL11 promoted CD8
Gao Q; Wang S; Chen X; Cheng S; Zhang Z; Li F; Huang L; Yang Y; Zhou B; Yue D; Wang D; Cao L; Maimela NR; Zhang B; Yu J; Wang L; Zhang Y
J Immunother Cancer; 2019 Feb; 7(1):42. PubMed ID: 30744691
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib enhances expression of effector molecules in anti-tumor CD8+ T lymphocytes by promoting Notch-nuclear factor-κB crosstalk.
Thounaojam MC; Dudimah DF; Pellom ST; Uzhachenko RV; Carbone DP; Dikov MM; Shanker A
Oncotarget; 2015 Oct; 6(32):32439-55. PubMed ID: 26431276
[TBL] [Abstract][Full Text] [Related]
3. Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma.
Kinoshita T; Kudo-Saito C; Muramatsu R; Fujita T; Saito M; Nagumo H; Sakurai T; Noji S; Takahata E; Yaguchi T; Tsukamoto N; Hayashi Y; Kaseda K; Kamiyama I; Ohtsuka T; Tomizawa K; Shimoji M; Mitsudomi T; Asamura H; Kawakami Y
Eur J Cancer; 2017 Nov; 86():15-27. PubMed ID: 28950145
[TBL] [Abstract][Full Text] [Related]
4. Anlotinib enhanced CD8
Luo J; Cheng K; Ji X; Gao C; Zhu R; Chen J; Xue W; Huang Q; Xu Q
Cancer Lett; 2024 Jun; 591():216892. PubMed ID: 38621459
[TBL] [Abstract][Full Text] [Related]
5. Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy.
Hubert P; Roncarati P; Demoulin S; Pilard C; Ancion M; Reynders C; Lerho T; Bruyere D; Lebeau A; Radermecker C; Meunier M; Nokin MJ; Hendrick E; Peulen O; Delvenne P; Herfs M
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33712445
[TBL] [Abstract][Full Text] [Related]
6. A cycle involving HMGB1, IFN-γ and dendritic cells plays a putative role in anti-tumor immunity.
Gao Q; Li F; Wang S; Shen Z; Cheng S; Ping Y; Qin G; Chen X; Yang L; Cao L; Liu S; Zhang B; Wang L; Sun Y; Zhang Y
Cell Immunol; 2019 Sep; 343():103850. PubMed ID: 30153900
[TBL] [Abstract][Full Text] [Related]
7. Infiltrating CD4+ T cells attenuate chemotherapy sensitivity in prostate cancer via CCL5 signaling.
Xiang P; Jin S; Yang Y; Sheng J; He Q; Song Y; Yu W; Hu S; Jin J
Prostate; 2019 Jun; 79(9):1018-1031. PubMed ID: 31018021
[TBL] [Abstract][Full Text] [Related]
8. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
[TBL] [Abstract][Full Text] [Related]
9. Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancer.
Takada K; Kashiwagi S; Goto W; Asano Y; Takahashi K; Takashima T; Tomita S; Ohsawa M; Hirakawa K; Ohira M
J Transl Med; 2018 Apr; 16(1):86. PubMed ID: 29615076
[TBL] [Abstract][Full Text] [Related]
10. CD8
Huang B; Liu R; Wang P; Yuan Z; Yang J; Xiong H; Zhang N; Huang Q; Fu X; Sun W; Li L
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32606053
[TBL] [Abstract][Full Text] [Related]
11. Docetaxel Upregulates HMGB1 Levels in Non-small Cell Lung Cancer.
Haruna M; Hirata M; Iwahori K; Kanazawa T; Yamamoto Y; Goto K; Kawashima A; Morimoto-Okazawa A; Funaki S; Shintani Y; Kumanogoh A; Wada H
Biol Pharm Bull; 2020; 43(3):399-403. PubMed ID: 32115500
[TBL] [Abstract][Full Text] [Related]
12. Low-dose docetaxel enhances the anti-tumour efficacy of a human umbilical vein endothelial cell vaccine.
Zhou L; Lu M; Zhong W; Yang J; Yin Y; Li M; Li D; Zhang S; Xu M
Eur J Pharm Sci; 2020 Jan; 142():105163. PubMed ID: 31756447
[TBL] [Abstract][Full Text] [Related]
13. The CXCR3 targeting chemokine CXCL11 has potent antitumor activity in vivo involving attraction of CD8+ T lymphocytes but not inhibition of angiogenesis.
Hensbergen PJ; Wijnands PG; Schreurs MW; Scheper RJ; Willemze R; Tensen CP
J Immunother; 2005; 28(4):343-51. PubMed ID: 16000952
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-33, a Potential Cytokine Expressed in Tumor Microenvironment Involves in Antitumor Immunotherapy Through Facilitates CD8
Li X; Lv Q; Feng Y; Gu Y; Xia R; Ma J; He H; Zhu Y
J Interferon Cytokine Res; 2018 Nov; 38(11):491-499. PubMed ID: 30452317
[TBL] [Abstract][Full Text] [Related]
15. [Clinicopathological characteristics of the CD8
Chai X; Sun Z; Li H; Zhu L; Liu X; Liu Y; Pei F; Chang Q
Beijing Da Xue Xue Bao Yi Xue Ban; 2024 Jun; 56(3):512-518. PubMed ID: 38864138
[TBL] [Abstract][Full Text] [Related]
16. CXCR6 deficiency impairs cancer vaccine efficacy and CD8
Karaki S; Blanc C; Tran T; Galy-Fauroux I; Mougel A; Dransart E; Anson M; Tanchot C; Paolini L; Gruel N; Gibault L; Lepimpec-Barhes F; Fabre E; Benhamouda N; Badoual C; Damotte D; Donnadieu E; Kobold S; Mami-Chouaib F; Golub R; Johannes L; Tartour E
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33692218
[TBL] [Abstract][Full Text] [Related]
17. Tumor-infiltrating CD36
Ao YQ; Gao J; Zhang LX; Deng J; Wang S; Lin M; Wang HK; Ding JY; Jiang JH
BMC Cancer; 2023 Apr; 23(1):367. PubMed ID: 37085798
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib augments lymphocyte stimulatory cytokine signaling in the tumor microenvironment to sustain CD8+T cell antitumor function.
Pellom ST; Dudimah DF; Thounaojam MC; Uzhachenko RV; Singhal A; Richmond A; Shanker A
Oncotarget; 2017 Jan; 8(5):8604-8621. PubMed ID: 28052005
[TBL] [Abstract][Full Text] [Related]
19. APE1 may influence CD4+ naïve T cells on recurrence free survival in early stage NSCLC.
Li Y; Zhao X; Xiao H; Yang B; Liu J; Rao W; Dai X; Li M; Dai N; Yang Y; Wang D
BMC Cancer; 2021 Mar; 21(1):233. PubMed ID: 33676448
[TBL] [Abstract][Full Text] [Related]
20. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
